2017

Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

Sanofi: FDA lifts clinical hold on fitusiran

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

Admelog®: Sanofi's FDA-Approved Insulin Lispro for Better Diabetes Management

Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec

Sanofi ends development of Clostridium difficile vaccine

Elias Zerhouni, President of Sanofi R&D, wins 'Executive of the Year' at annual Scrip Awards

Sanofi updates information on dengue vaccine

Sanofi, Principia agree to develop multiple sclerosis drug candidate

Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy

Sanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed

Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®

Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

Sanofi's €170 Million Investment: New Vaccine Production Facility in France

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular

Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union

Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial

Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma

Sanofi rated AA by Scope Ratings

Sanofi completes the acquisition of Protein Sciences

Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®

Sanofi: Online Availability of Sanofi Group's Half-Year Financial Report for 2017

Sanofi Raises FY 2017 Business EPS(1) Guidance to Broadly Stable at CER(2)

Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi Acquires Protein Sciences and Expands Vaccine Range

Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...

Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union

Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients